Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Beyond FDG PET in Epilepsy: Radiotracers Targeting Neuroreceptors and Neural Proteins.

AJNR. American journal of neuroradiology·2026
Same author

A potential Adjunctive Role of 7T MRI and Amino-Acid PET in Localizing MRI-Occult Functional Pituitary Microadenomas: A Scoping Review.

AJNR. American journal of neuroradiology·2026
Same author

Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio.

JAMA neurology·2026
Same author

Identification and quantification of Hypocretin-1/Orexin-A 1-14 and 1-16 fragments in immunopurified cerebrospinal fluid using LC-MS: Comparison with radioimmunoassay (RIA) determinations.

Sleep medicine·2026
Same author

Abnormal amyloid PET usually represents intermediate/high Alzheimer's disease neuropathologic change.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

From Training to Independent Practice in Radiology: Reflections and Early-Career Lessons.

Radiology. Imaging cancer·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Alicia Algeciras-Schimnich1, Susan Ashrafzadeh-Kian1, Joshua A Bornhorst1

  • 1Mayo Clinic, Rochester, MN, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

血p-tau217测定精确检测粉样蛋白病理,有助于符合粉样蛋白降低疗法的资格. 双切点方法优化了临床实践中的准确性,并最大限度地减少了假阳性.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 生物标志物发现发现
  • 阿尔茨海默氏症疾病研究研究

背景情况:

  • 血p-tau217测定是评估粉样蛋白病理学的新兴工具.
  • 准确检测粉样蛋白对于启动粉样蛋白降低疗法至关重要.
  • 实施了双切点策略,以提高诊断精度和减少假阳性.

研究的目的:

  • 为了前性地评估血p-tau217试验的诊断性能.
  • 通过使用预定义的切断点来评估测试在识别粉样蛋白病理方面的准确性.
  • 在临床环境中验证双切点方法的实用性.

主要方法:

  • 被考虑接受lecanemab治疗的93名患者被纳入.
  • 使用Fujirebio Lumipulse测定法测量了血p-tau217水平.
  • 通过粉样蛋白-PET和/或CSF p-tau181/Aβ42.2确认了粉样蛋白病理.

主要成果:

  • 血p-tau217测定显示,粉样蛋白阳性的诊断准确率为96%.
  • 83%的患者有阳性血p-tau217结果,6%是负的,11%是中间的.
  • 对于最终结果的积极和消极预测值分别为97%和83%.

结论:

  • 卢米脉冲血p-tau217试验显示了对粉样蛋白病理学的可靠诊断准确性.
  • 两切点解释方法对于评估治疗资格是有效的.
  • 这种方法支持不同患者队列中的血p-tau217的临床实用性.